Department of Biological, Chemical and Pharmaceutical Sciences and Technologies (STEBICEF), University of Palermo, Palermo, Italy; Institute of Oncology Research, Faculty of Biomedical Sciences, USI, Bellinzona, Switzerland.
Oncology Institute of Southern Switzerland, Bellinzona, Switzerland,; Faculty of Biomedical Sciences, USI, Lugano, Switzerland.
Pharmacol Ther. 2020 Jul;211:107552. doi: 10.1016/j.pharmthera.2020.107552. Epub 2020 Apr 17.
Anti-tubulin agents constitute a large class of compounds with broad activity both in solid tumors and hematologic malignancies, due to the interference with microtubule dynamics. Since microtubules play crucial roles in the regulation of the mitotic spindles, the interference with their function usually leads to a block in cell division with arrest at the metaphase/anaphase junction of mitosis, followed to apoptosis. This explains the reason why tubulin-binding agents (TBAs) proved to be extremely active in patients with cancer. Several anti-tubulin agents are indicated in the treatment of patients with lymphomas both alone and in combination chemotherapy regimens. The article reviews the literature on classic and more recent anti-tubulin agents, providing an insight into their mechanisms of action and their use in the treatment of lymphoma.
抗微管药物是一大类化合物,由于干扰微管动力学,在实体瘤和血液恶性肿瘤中具有广泛的活性。由于微管在调节有丝分裂纺锤体中起着至关重要的作用,因此干扰其功能通常会导致细胞分裂停滞在有丝分裂的中期/后期交界处,随后发生细胞凋亡。这就解释了为什么微管结合剂(TBAs)在癌症患者中被证明具有极强的活性。有几种抗微管药物单独或联合化疗方案用于治疗淋巴瘤患者。本文综述了经典和最新的抗微管药物的文献,深入探讨了它们的作用机制及其在淋巴瘤治疗中的应用。